KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease

We describe a metastatic colorectal cancer (mCRC) patient, treated with first-line FIr-B/FOx (5-fluorouracil, irinotecan, bevacizumab, oxaliplatin) therapy, with aggressive and resistant disease. KRAS, NRAS, BRAF, PI3KCA were analyzed in primary tumor and liver metastasis. KRAS c.34G>A mutation was detected in primary tumor and liver metastasis, which, additionally, revealed two rare PI3KCA mutations (c.1633G>C, c.1645G>C). The c.1645G>C was never reported in CRC. Akt/p-AktSer473, PTEN, mismatch repair (MMR), epidermal growth factor receptor (EGFR) expression was evaluated.

Source: Human Pathology - February 3, 2018 Category: Pathology Authors: Alessandra Tessitore, Gemma Bruera, Valentina Mastroiaco, Katia Cannita, Alessio Cortellini, Valentina Cocciolone, Antonella Dal Mas, Giuseppe Calvisi, Francesca Zazzeroni, Corrado Ficorella, Enrico Ricevuto, Edoardo Alesse Tags: Case Study Source Type: research